Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

electroCore Aims Noninvasive Neurostimulation At The Masses

This article was originally published in Start Up

Executive Summary

Armed with a $40 million Series A financing, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. With drug firms upping their interest in so-called “electroceuticals,” it could signal a shift away from certain pharmaceutical treatments.

You may also be interested in...



Electroceuticals: Drug-Like Effects, Without The Drugs

Electroceuticals could replace the use of pharmaceuticals in many chronic diseases, offering effective treatments without, perhaps, side effects. Medtechs pioneering these next-gen neuromodulation devices are sparking investor interest.

Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?

The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.

Deals Of The Week Looks At Pricing Conundrums

New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel